- 1、本文档共135页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
《ckdmbd规范治疗》课件
* Vitamin D Suppresses PTH but With Potential Trade-Offs in Phosphorous and Calcium Levels3 Months Following Initiation * Active vitamin D and its derivatives reduce the PTH levels, but at the same time they also elevate calcium and phosphorus levels. Increased levels of serum calcium and phosphorus are associated with adverse events such as soft tissue calcification. * * The JSDT guidelines were drafted on the base that PTH should be controlled with the serum phosphorus and serum calcium levels remaining under optimal control. Under these circumstances , the regulation of PTH is limited by the range of target values for serum phosporus and calcium. * Key Point: The primary objective of the study was to observe the effects of cinacalcet on SHPT patients within NKF-K/DOQI? targets for PTH but who had uncontrolled Ca x P (? 55 mg2/dL2). Notes: A conversion of 1.875 x biPTH = PTH was used in the following presentations of these TARGET and CONTROL data. PTX术后10个月 骨痛消失,食欲改善,Hb上升,干体重增加5Kg 对于SHPT患者来说,做了PTx或PEIT 已经发生的型体改变 已经形成的血管钙化 通常很难改善 CKD-MBD的现状和展望 从 K/DOQI来看,还存在达标率的问题 Kim J et al. J Am Soc Nephrol 2003;14:269A Target 0 10 20 30 40 50 60 PTH Ca x P Calcium Phosphorus All 4 targets 70 Patients achieving target (%) n = 3540 27 51 44 62 8 达标率(%) 钙 磷 钙磷乘积 iPTH DOPPS-i 40.5 40.8 56.6 21.4 DOPPS-ii 42.5 44.4 61.4 26.2 日本 39 33 17 67 一中心 80.4 38.4 49.3 43.7 纵观整个CKD-MBD指南仅有两条建议按GRADE标准达到1A,说明今后我们还要在循证医学上做更多的工作来不断的完善这一指南。 我国目前对CKD-MBD的治疗现状: 很少早期监测与治疗 大多在严重SHPT(已经出现骨骼畸形)才开始使用活性VitD制剂 治疗方法、药物剂量、疗程不统一 缺乏严密的监测(尤其是PTH等) 若PTH过度抑制,ABD随之发生 血钙、磷及CaXP过高,转移性钙化发生 PTX未得到普及 谢 谢! * Key Points 1,25-dihydroxyvitamin D (1,25(OH)2D3) levels start falling much earlier in CKD before the rise in PTH is observed. The changes in 1,25(OH)2D3 have not previously been described given the lack of data in this earlier population.1 Note that secondary HPT begins to occur at eGFR levels of approximately 45 mL/min/1.73 m2, similar to the point wher
文档评论(0)